[go: up one dir, main page]

TR200502508T2 - Use of IL-18 Inhibitors. - Google Patents

Use of IL-18 Inhibitors.

Info

Publication number
TR200502508T2
TR200502508T2 TR2005/02508T TR200502508T TR200502508T2 TR 200502508 T2 TR200502508 T2 TR 200502508T2 TR 2005/02508 T TR2005/02508 T TR 2005/02508T TR 200502508 T TR200502508 T TR 200502508T TR 200502508 T2 TR200502508 T2 TR 200502508T2
Authority
TR
Turkey
Prior art keywords
inhibitors
arthritis
medicament
prevention
preparation
Prior art date
Application number
TR2005/02508T
Other languages
Turkish (tr)
Inventor
Chvatchko Yolande
Dinarello Charles
Plater-Zyberk Christine
Van Deventer Santer
Rubinstein Menachem
Novick Daniela
Kim Soo-Hyun
Original Assignee
Applied Research Systems Ar� Holding N.V.
Yeda Research And Developmbnt Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ar� Holding N.V., Yeda Research And Developmbnt Company Ltd. filed Critical Applied Research Systems Ar� Holding N.V.
Publication of TR200502508T2 publication Critical patent/TR200502508T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Buluş, artritin, özellikle römatoid artritın tedavi ve/veya önlenmesi için bir ilacın hazırlanmasında IL-18 inhıbitörlerinin kullanımı ile ilgilidir.The invention relates to the use of IL-18 inhibitors in the preparation of a medicament for the treatment and / or prevention of arthritis, particularly rheumatoid arthritis.

TR2005/02508T 2000-02-21 2001-02-20 Use of IL-18 Inhibitors. TR200502508T2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00103597 2000-02-21
EP00103590 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23

Publications (1)

Publication Number Publication Date
TR200502508T2 true TR200502508T2 (en) 2007-04-24

Family

ID=27439934

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2005/02508T TR200502508T2 (en) 2000-02-21 2001-02-20 Use of IL-18 Inhibitors.
TR2002/02030T TR200202030T2 (en) 2000-02-21 2001-02-20 The use of IL-18 inhibitors.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/02030T TR200202030T2 (en) 2000-02-21 2001-02-20 The use of IL-18 inhibitors.

Country Status (30)

Country Link
US (1) US20030157094A1 (en)
EP (1) EP1257292B1 (en)
JP (1) JP4744763B2 (en)
KR (3) KR20020086540A (en)
CN (1) CN1322897C (en)
AT (1) ATE506959T1 (en)
AU (2) AU4063601A (en)
BG (1) BG66134B1 (en)
BR (1) BR0108514A (en)
CA (2) CA2683009C (en)
CY (1) CY1111687T1 (en)
CZ (1) CZ304485B6 (en)
DE (1) DE60144514D1 (en)
DK (1) DK1257292T3 (en)
EA (1) EA005583B1 (en)
EE (1) EE05423B1 (en)
HR (1) HRP20020652A2 (en)
HU (1) HU227752B1 (en)
IL (2) IL151388A0 (en)
ME (1) ME00546B (en)
MX (1) MXPA02008079A (en)
NO (1) NO331971B1 (en)
NZ (3) NZ546294A (en)
PL (1) PL206549B1 (en)
PT (1) PT1257292E (en)
RS (1) RS51737B (en)
SI (1) SI1257292T1 (en)
SK (1) SK288032B6 (en)
TR (2) TR200502508T2 (en)
WO (1) WO2001062285A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151044A0 (en) * 2000-02-10 2003-04-10 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
RS51737B (en) * 2000-02-21 2011-10-31 Laboratoires Serono Sa. USE OF IL-18 INHIBITOR
EP2357002A1 (en) 2000-10-11 2011-08-17 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP4502580B2 (en) * 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Use of IL-18 inhibitors for the treatment or prevention of sepsis
AU2002341321A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2513584A1 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
EP1621616A4 (en) 2003-04-30 2007-07-04 Japan Science & Tech Agency ANTIHUMAN INTERLEUKIN-18 HUMAN ANTIBODY, FRAGMENT THEREOF AND METHOD OF USING SAME
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AU2005258569B2 (en) 2004-06-30 2012-05-03 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use thereof
JP5595632B2 (en) 2004-07-16 2014-09-24 敦生 関山 IL-18 receptor antagonist and pharmaceutical composition comprising said antagonist
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
ATE529433T1 (en) 2005-06-10 2011-11-15 Ares Trading Sa METHOD FOR PURIFYING AN IL-18 BINDING PROTEIN
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
PE20080262A1 (en) 2006-05-25 2008-04-30 Glaxo Group Ltd HUMANIZED ANTIBODY AGAINST INTERLEUQUIN-18
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
PH12016500425B1 (en) * 2013-09-05 2022-07-29 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
JP7274259B2 (en) * 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
CN106109497A (en) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 The stem cell medicine for the treatment of liver cirrhosis
CN106834449B (en) * 2017-01-10 2019-04-30 东南大学 Interleukin-21 receptor associated with primary biliary cholangitis and its application
WO2019238893A1 (en) * 2018-06-14 2019-12-19 Universite de Bordeaux Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1
WO2023286694A1 (en) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 Medicinal composition for treating inflammatory bowel disease
CN117647645B (en) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Application of LBP, ATF6 and M-CSFR combination in preparation of product for diagnosing autoimmune liver disease and kit
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
PT936923E (en) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology BLENDING OF TNFALFA AND IL-12 IN THERAPY
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4026923B2 (en) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 Polypeptide
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (en) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 Interleukin 18-binding protein
AR022952A1 (en) * 1999-03-19 2002-09-04 Smithkline Beecham Corp MONOCLONAL ANTIBODY OF ROEDOR SPECIFICALLY NEUTRALIZING FOR HUMAN INTERLEUQUINE-18, A FAB NEUTRALIZING FRAGMENT OR FRAGMENT F (AB ') 2, A COMPLEMENTARITY REGION OF IMMONOGLOBULIN LIGHT CHAIN (CDR), WHICH MAKES IT COMPRESSED , THE
IL151044A0 (en) * 2000-02-10 2003-04-10 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
RS51737B (en) * 2000-02-21 2011-10-31 Laboratoires Serono Sa. USE OF IL-18 INHIBITOR
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
NO20023962L (en) 2002-08-20
KR20070087256A (en) 2007-08-27
EA005583B1 (en) 2005-04-28
YU60402A (en) 2005-09-19
CN1404400A (en) 2003-03-19
CA2683009A1 (en) 2001-08-30
HUP0300061A3 (en) 2005-09-28
RS51737B (en) 2011-10-31
NZ520122A (en) 2005-04-29
AU2001240636B2 (en) 2005-10-13
CY1111687T1 (en) 2015-10-07
SI1257292T1 (en) 2011-08-31
NO20023962D0 (en) 2002-08-20
AU4063601A (en) 2001-09-03
PL206549B1 (en) 2010-08-31
MXPA02008079A (en) 2003-02-27
BG66134B1 (en) 2011-06-30
SK288032B6 (en) 2012-12-03
HU227752B1 (en) 2012-02-28
CA2399298A1 (en) 2001-08-30
AU2001240636B8 (en) 2005-11-03
ATE506959T1 (en) 2011-05-15
CA2683009C (en) 2014-09-23
PT1257292E (en) 2011-07-05
PL357554A1 (en) 2004-07-26
NO331971B1 (en) 2012-05-14
IL151388A (en) 2009-09-01
HRP20020652A2 (en) 2004-12-31
KR20070057282A (en) 2007-06-04
KR20020086540A (en) 2002-11-18
CZ304485B6 (en) 2014-05-28
US20030157094A1 (en) 2003-08-21
JP4744763B2 (en) 2011-08-10
HUP0300061A2 (en) 2003-04-28
NZ546294A (en) 2008-02-29
ME00546B (en) 2011-10-10
BR0108514A (en) 2002-12-17
EE200200463A (en) 2003-12-15
CZ20022843A3 (en) 2003-02-12
WO2001062285A1 (en) 2001-08-30
DK1257292T3 (en) 2011-07-18
TR200202030T2 (en) 2003-01-21
HK1051965A1 (en) 2003-08-29
NZ535299A (en) 2006-06-30
CN1322897C (en) 2007-06-27
EA200200890A1 (en) 2003-02-27
CA2399298C (en) 2014-04-15
EP1257292A1 (en) 2002-11-20
JP2003523403A (en) 2003-08-05
EP1257292B1 (en) 2011-04-27
IL151388A0 (en) 2003-04-10
DE60144514D1 (en) 2011-06-09
BG107018A (en) 2003-09-30
EE05423B1 (en) 2011-06-15
SK12082002A3 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
TR200502508T2 (en) Use of IL-18 Inhibitors.
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
TR200401264T4 (en) The combination of CB1-receptor-antagonist and cybutamine, pharmaceutical compositions containing them and their use in the treatment of obesity.
TR200202194T2 (en) Polyglutamic acid-camptothecin compounds and preparation methods
NO20031672D0 (en) Aza and polyazanaphthalenylcarboxamides for use as HIV integrase inhibitors
HUP0301577A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
TR200002759T2 (en) Cabergoline use in the treatment of leg numbness syndrome.
CY1110385T1 (en) Use of IL-18 inhibitors for the treatment and / or prevention of atherosclerosis
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
IT1320080B1 (en) COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE.
MY137620A (en) Therapeutic treatment
FI20000635A0 (en) Use of COMT inhibitors as an analgesic
BR0012675A (en) Use of il-18 Inhibitors
YU57803A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
BR0111785A (en) Compositions and methods for treating candidiasis
CY1108053T1 (en) UNION OF CYAMEMAZINE AND A FORMULATED NEUROLIPTIC
TR200002939T2 (en) Paroxetine maleate
MXPA04001230A (en) Use of il-18 inhibitors in hypersensitivity disorders.
TR200502061T2 (en) Use of IL-18 inhibitors.
MD2228G2 (en) use of isothiouronic derivatives in the treatment and prophylaxis of intestinal atony
WO2003047571A3 (en) Use of a kmo inhibitor for producing a pharmaceutical composition
AP1731A (en) Use of an inhibitor of the renin-angiotensin system for the manufacture of a medicament or prevention of lipodystrophy syndorme.
ES2187440T3 (en) USE OF OROSOMUCOID IN A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF ACUTE PANCREATITIS.
MY120631A (en) Novel pharmaceutical combination having analgesic activity